Objective: To test the impact of Thulium laser enucleation of the prostate (ThuLEP) on erectile and ejaculatory functions, on lower urinary tract symptoms and on quality of life (QoL). Methods: From July 2013 to May 2015, we prospectively evaluated 177 patients with LUTS related to benign prostatic hyperplasia. All patients were assessed with the International Index of Erectile Function (IIEF-5), Male Sexual Health Questionnaire-Ejaculatory Disease (MSHQ-EjD), International Prostate Symptom Score (IPSS), QoL, PSA and uroflowmetry before and at 4 and 8 months after surgery. Results: Erectile function did not show variation with IIEF-5 preoperative score 22.49 ± 1.8 and postoperative score 22.14 ± 3.1 (p = 0.195) and 22.18 ± 3.2 (p = 0.26) at 4 and 8 months after treatment. The ejaculatory function on the MSHQ-EjD test indicated the reduction of ejaculation, changing from 14.90 ± 6.88 to 5.51 ± 4.17 (p < 0.0001) and 5.38 ± 3.93 (p < 0.0001) at 4 and 8 months follow-up. IPSS score decreased from preoperative 21.12 ± 5.81 to 3.14 ± 3.16 (p < 0.0001) and 3.08 ± 3.12 (p < 0.0001) 4 and 8 months after surgery. PSA decreased from 4.50 ± 3.72 to 1.39 ± 1.04 (p < 0.0001) and 1.47 ± 1.14 ng/ml (p < 0.0001) at 4 and 8 months follow-up, while QoL score improved from 5.41 ± 0.69 to 0.57 ± 0.84 (p < 0.0001) and 0.51 ± 0.80 (p < 0.0001) at 4 and 8 months follow-up. Conclusions: ThuLEP does not affect erectile function and determines the resolution of LUTS with improvement of QoL. Loss of ejaculation did not impair the sexual intercourse activities of the patients.

Keywords:
Benign prostatic hyperplasia, Laser surgery, Sexual function, Thulium laser enucleation of the prostate
1.
Hoffman RM, MacDonald R, Slaton JW, Wilt TJ: Laser prostatectomy versus transurethral resection for treating benign prostatic obstruction: a systematic review. J Urol 2003;169:210-215.
2.
Serretta V, Morgia G, Fondacaro L, Curto G, Lo bianco A, et al; Members of the Sicilian-Calabrian Society of Urology: Open prostatectomy for benign prostatic enlargement in southern Europe in the late 1990s: a contemporary series of 1800 interventions. Urology 2002;60:623-627.
3.
Tubaro A, Carter S, Hind A, Vicentini C, Miano L: A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia. J Urol 2001;166:172-176.
4.
Tietze S, Kiehle B, Krause J, Behrendt W, Hamza A: Laser therapy for bladder outlet obstruction: a prospective analysis of all patients receiving treatment with the GreenLight XPS 180-watt laser system after introduction at a single center. Urol Int 2015;95:293-299.
5.
Altay B, Erkurt B, Kiremit MC, Horuz R, Guzelburc V, et al: A comparison of 120 W laser photoselective vaporization versus transurethral resection of the prostate for bladder outlet obstruction by prostate cancer. Urol Int 2015;94:326-329.
6.
Gravas S, Bachmann A, Reich O, Roehrborn CG, Gilling PJ, et al: Critical review of lasers in benign prostatic hyperplasia (BPH). BJU Int 2011;107:1030-1043.
7.
Kuntz RM, Lehrich K, Ahyai SA: Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol 2008;53:160-166.
8.
Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, et al; European Association of Urology: EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118-140.
9.
Rosen RC, Catania JA, Althof SE, Pollack LM, O'Leary M, et al: Development and validation of four-item version of male sexual health questionnaire to assess ejaculatory dysfunction. Urology 2007;69:805-809.
10.
Saredi G, Pirola GM, Pacchetti A, Lovisolo JA, Borroni G, et al: Evaluation of the learning curve for Thulium laser enucleation of the prostate with the aid of a simulator tool but without tutoring: comparison of two surgeons with different levels of endoscopic experience. BMC Urol 2015;15:49.
11.
Herrmann TR, Bach T, Imkamp F, Georgiou A, Burchardt M, et al: Thulium laser enucleation of the prostate (ThuLEP): transurethral anatomical prostatectomy with laser support. Introduction of a novel technique for the treatment of benign prostatic obstruction. World J Urol 2010;28:45-51.
12.
Xia SJ, Zhuo J, Sun XW, Han BM, Shao Y, et al: Thulium laser versus standard transurethral resection of the prostate: a randomized prospective trial. Eur Urol 2008;53:382-389.
13.
Kyriazis I, Świniarski PP, Jutzi S, Wolters M, Netsch C, et al: Transurethral anatomical enucleation of the prostate with Tm:YAG support (ThuLEP): review of the literature on a novel surgical approach in the management of benign prostatic enlargement. World J Urol 2015;33:525-530.
14.
Carmignani L, Bozzini G, Macchi A, Maruccia S, Picozzi S, et al: Sexual outcome of patients undergoing Thulium laser enucleation of the prostate for benign prostatic hyperplasia. Asian J Androl 2015;17:802-806.
15.
Iacono F, Prezioso D, Di Lauro G, Romeo G, Ruffo A, et al: Efficacy and safety profile of a novel technique, ThuLEP (Thulium laser enucleation of the prostate) for the treatment of benign prostatic hypertrophy. Our experience on 148 patients. BMC Surg 2012;12(suppl 1):S21.
16.
Gross AJ, Netsch C, Knipper S, Hölzel J, Bach T: Complications and early postoperative outcome in 1080 patients after thulium vapoenucleation of the prostate: results at a single institution. Eur Urol 2013;63:859-867.
17.
Klett DE, Tyson MD 2nd, Mmeje CO, Nunez-Nateras R, Chang YH, et al: Patient-reported sexual outcomes after Holmium laser enucleation of the prostate: a 3-year follow-up study. Urology 2014;84:421-426.
18.
Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, et al: Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637-649.
19.
Brookes ST, Donovan JL, Peters TJ, Abrams P, Neal DE: Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. BMJ 2002;324:1059-1061.
20.
Briganti A, Naspro R, Gallina A, Salonia A, Vavassori I, et al: Impact on sexual function of holmium laser enucleation versus transurethral resection of the prostate: results of a prospective, 2-center, randomized trial. J Urol 2006;175:1817-1821.
21.
Marra G, Sturch P, Oderda M, Tabatabaei S, Muir G, et al: Systematic review of lower urinary tract symptoms/benign prostatic hyperplasia surgical treatments on men's ejaculatory function: time for a bespoke approach? Int J Urol 2016;23:22-35.
22.
Nakamura M, Fujimura T, Nagata M, Hosoda C, Suzuki M, et al: Association between lower urinary tract symptoms and sexual dysfunction assessed using the core lower urinary tract symptom score and international index of erectile function-5 questionnaires. Aging Male 2012;15:111-114.
23.
Neill MG, Gilling PJ: Randomized trial comparing holmium laser enucleation of prostate with plasmakinetic enucleation of prostate for treatment of benign prostatic hyperplasia. Urology 2006;68:1020-1024.
24.
Chen YB, Chen Q, Wang Z, Peng YB, Ma LM, et al: A prospective, randomized clinical trial comparing plasmakinetic resection of the prostate with Holmium laser enucleation of the prostate based on a 2-year follow-up. J Urol 2013;189:217-222.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.